Merck's juggernaut diabetes drug Januvia now faces renewed scrutiny five years after an endocrinologist found that lab rats given the medicine were more susceptible to pancreatic cancer, according to a report in The New York Times.
After followup studies by the same doctor, Peter Butler, the Food and Drug Administration and the European Medicines Agency have begun investigations that could lead to new warnings on Whitehouse Station-based Merck's Januvia and other drugs in its class, according to The Times report.
In March, the FDA also said it was reviewing unpublished findings by a group of academic researchers that suggest pre-cancerous cellular changes associated with Type 2 diabetes drugs that include Januvia, Bristol-Myers Squibb Co.’s Byetta and Novo Nordisk A/S’s Victoza.
No comments:
Post a Comment